Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Axogen, Inc.AXGN · Entity 4297 | Chief Innovation Officer | March 16, 2026 | March 18, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Axogen, Inc.
Report date March 16, 2026 · Filed March 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 262,781 |
Ending reported balance
After 2026-03-16 transaction · row 4
4 source rows · reconciled sequenceRow 1 · 2026-03-16 · Exercise / conversion · Acquired 6,363 · Balance 259,297 F1: This reflects the number of restricted stock units ("RSUs") that vested on March 16, 2026. Row 2 · 2026-03-16 · Tax withholding · Disposed 2,870 · Balance 256,427 F2: This represents the number of shares of Common Stock that have been withheld by the issuer to satisfy tax withholding and remittance obligations in connection with the net settlement of the RSUs and does not represent an open market sale. Row 3 · 2026-03-16 · Exercise / conversion · Acquired 11,575 · Balance 268,002 F1: This reflects the number of restricted stock units ("RSUs") that vested on March 16, 2026. Row 4 · 2026-03-16 · Sale · Disposed 5,221 · Balance 262,781 F2: This represents the number of shares of Common Stock that have been withheld by the issuer to satisfy tax withholding and remittance obligations in connection with the net settlement of the RSUs and does not represent an open market sale. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 6,363 |
Reported balance
After 2026-03-16 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-03-16 · Exercise / conversion · Acquired 6,363 · Balance 6,363 F3: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock. F4: All shares of Axogen Inc. common stock underlying the restricted stock units are fully vested on March 16, 2026 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vested on March 16, 2024 (24 months from the grant date) and an additional 25% of the aggregate shares vested each 12 months thereafter. Vested shares are delivered to the reporting person upon the vesting dates. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 11,575 |
Reported balance
After 2026-03-16 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-03-16 · Exercise / conversion · Acquired 11,575 · Balance 11,575 F3: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock. F5: All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on March 16, 2027 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vested on March 16, 2025 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares are delivered to the reporting person upon the vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: This reflects the number of restricted stock units ("RSUs") that vested on March 16, 2026.
F2: This represents the number of shares of Common Stock that have been withheld by the issuer to satisfy tax withholding and remittance obligations in connection with the net settlement of the RSUs and does not represent an open market sale.
F3: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock.
F4: All shares of Axogen Inc. common stock underlying the restricted stock units are fully vested on March 16, 2026 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vested on March 16, 2024 (24 months from the grant date) and an additional 25% of the aggregate shares vested each 12 months thereafter. Vested shares are delivered to the reporting person upon the vesting dates.
F5: All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on March 16, 2027 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vested on March 16, 2025 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares are delivered to the reporting person upon the vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 27, 2022 Filed Dec 29, 2022 02:34 UTC | Axogen, Inc. AXGN · Entity 4297 | Exercise / conversionCommon Stock | 20,000 | $5.09 | $101,800.00 |
DisclosureSEC source: 0000805928-22-000133 · wf-form4_167228127578446.xml · nonDerivative · entry 1 DeVinney Erick Wayne · CIK 0001595972 · VP Peripheral Nerve Science 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 116,752 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: This Form is being filed to report the exercise of a stock option for a total of 20,000 shares by means of a stock swap. A stock swap is a method of exercising a stock option in which the option holder pays the exercise price using shares of stock already owned. As a result of this stock, the Reporting Person, on a net basis, acquired ownership of an additional 9,216 shares of common stock. Read SEC document |
| December 27, 2022 Filed Dec 30, 2022 01:56 UTC | Axogen, Inc. AXGN · Entity 4297 | Exercise / conversionRestricted Stock Units · Derivative | 750 | $0.00 | $0.00 |
DisclosureSEC source: 0000805928-22-000145 · wf-form4_167236538787713.xml · derivative · entry 3 DeVinney Erick Wayne · CIK 0001595972 · VP Peripheral Nerve Science 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 750 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock. F4 · derivative.exercise_date: All shares of AxoGen Inc. common stock underlying the restricted stock units vested on December 27, 2022 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on December 27, 2020 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. F4 · derivative.expiration_date: All shares of AxoGen Inc. common stock underlying the restricted stock units vested on December 27, 2022 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on December 27, 2020 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Read SEC document |
| December 27, 2022 Filed Dec 30, 2022 01:56 UTC | Axogen, Inc. AXGN · Entity 4297 | Tax withholdingCommon Stock | 187 | $9.44 | $1,765.28 |
DisclosureSEC source: 0000805928-22-000145 · wf-form4_167236538787713.xml · nonDerivative · entry 2 DeVinney Erick Wayne · CIK 0001595972 · VP Peripheral Nerve Science 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 106,531 F2 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. Read SEC document |
| December 27, 2022 Filed Dec 30, 2022 01:56 UTC | Axogen, Inc. AXGN · Entity 4297 | Exercise / conversionCommon Stock | 750 | $0.00 | $0.00 |
DisclosureSEC source: 0000805928-22-000145 · wf-form4_167236538787713.xml · nonDerivative · entry 1 DeVinney Erick Wayne · CIK 0001595972 · VP Peripheral Nerve Science 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 106,718 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: This reflects the number of restricted stock units that vested on December 27, 2022. Read SEC document |
| July 19, 2022 Filed Jul 20, 2022 20:01 UTC | Axogen, Inc. AXGN · Entity 4297 | Disposition to issuerCommon Stock | 405 | $8.40 | $3,402.00 |
DisclosureSEC source: 0000805928-22-000092 · wf-form4_165834728313660.xml · nonDerivative · entry 2 DeVinney Erick Wayne · CIK 0001595972 · VP Peripheral Nerve Science 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 96,752 F2 · shares: The reported shares were sold, in compliance with company policy as to delivery of compensation based equity, with proceeds from such being used to cover the Reporting Person's tax withholding liability in connection with a portion of a performance stock award that vested on July 19, 2022. Read SEC document |
| July 18, 2022 Filed Jul 20, 2022 20:01 UTC | Axogen, Inc. AXGN · Entity 4297 | GrantCommon Stock | 1,579 | $0.00 | $0.00 |
DisclosureSEC source: 0000805928-22-000092 · wf-form4_165834728313660.xml · nonDerivative · entry 1 DeVinney Erick Wayne · CIK 0001595972 · VP Peripheral Nerve Science 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 94,157 F1 · shares: This reflects the number of shares that vested as of July 18, 2022 upon the attainment of certain performance criteria. Read SEC document |
| March 16, 2022 Filed Mar 18, 2022 20:03 UTC | Axogen, Inc. AXGN · Entity 4297 | GrantEmployee Stock Option (right to purchase) · Derivative | 23,738 | $0.00 Strike: $8.20 | $0.00 |
DisclosureSEC source: 0000805928-22-000028 · wf-form4_164763377704238.xml · derivative · entry 5 DeVinney Erick Wayne · CIK 0001595972 · VP Peripheral Nerve Science 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,738 Underlying: Common Stock · 23,738 shares Expires 2032-03-16 F6 · derivative.exercise_date: All shares of Axogen, Inc. common stock underlying the employee stock option will be fully vested on March 16, 2026 (4 years from the option grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on March 16, 2024 (24 months from the option grant date) and an additional 12.5% of the aggregate shares vest each 6 months thereafter. Read SEC document |
| March 16, 2022 Filed Mar 18, 2022 20:03 UTC | Axogen, Inc. AXGN · Entity 4297 | GrantRestricted Stock Units · Derivative | 25,450 | $0.00 | $0.00 |
DisclosureSEC source: 0000805928-22-000028 · wf-form4_164763377704238.xml · derivative · entry 4 DeVinney Erick Wayne · CIK 0001595972 · VP Peripheral Nerve Science 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,450 Underlying: Common Stock · 25,450 shares Expires not disclosed F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock. F5 · derivative.exercise_date: All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on March 16, 2026 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregateshares vest on March 16, 2024 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date. F5 · derivative.expiration_date: All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on March 16, 2026 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregateshares vest on March 16, 2024 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date. Read SEC document |
| March 16, 2022 Filed Mar 18, 2022 20:03 UTC | Axogen, Inc. AXGN · Entity 4297 | Exercise / conversionRestricted Stock Units · Derivative | 6,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000805928-22-000028 · wf-form4_164763377704238.xml · derivative · entry 3 DeVinney Erick Wayne · CIK 0001595972 · VP Peripheral Nerve Science 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,000 Underlying: Common Stock · 6,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock. F4 · derivative.exercise_date: All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on March 16, 2024 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on March 16, 2022 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date. F4 · derivative.expiration_date: All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on March 16, 2024 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on March 16, 2022 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date. Read SEC document |
| March 16, 2022 Filed Mar 18, 2022 20:03 UTC | Axogen, Inc. AXGN · Entity 4297 | Tax withholdingCommon Stock | 1,497 | $7.97 | $11,931.09 |
DisclosureSEC source: 0000805928-22-000028 · wf-form4_164763377704238.xml · nonDerivative · entry 2 DeVinney Erick Wayne · CIK 0001595972 · VP Peripheral Nerve Science 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 92,578 F2 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. Read SEC document |
| March 16, 2022 Filed Mar 18, 2022 20:03 UTC | Axogen, Inc. AXGN · Entity 4297 | Exercise / conversionCommon Stock | 6,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000805928-22-000028 · wf-form4_164763377704238.xml · nonDerivative · entry 1 DeVinney Erick Wayne · CIK 0001595972 · VP Peripheral Nerve Science 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 94,075 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: This reflects the number of restricted stock units that became vested as of March 16, 2022. Read SEC document |
| February 15, 2022 Filed Feb 17, 2022 21:05 UTC | Axogen, Inc. AXGN · Entity 4297 | Tax withholdingCommon Stock | 357 | $8.42 | $3,005.94 |
DisclosureSEC source: 0000805928-22-000008 · wf-form4_164513189026580.xml · nonDerivative · entry 2 DeVinney Erick Wayne · CIK 0001595972 · VP Peripheral Nerve Science 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,075 F3 · shares: The reported shares were sold, in compliance with company policy as to delivery of compensation based equity, with proceeds from such being used to cover the Reporting Person's tax withholding liability in connection with a portion of a performance stock award that vested on February 15, 2022. Read SEC document |
| February 15, 2022 Filed Feb 17, 2022 21:05 UTC | Axogen, Inc. AXGN · Entity 4297 | GrantCommon Stock | 1,181 | $0.00 | $0.00 |
DisclosureSEC source: 0000805928-22-000008 · wf-form4_164513189026580.xml · nonDerivative · entry 1 DeVinney Erick Wayne · CIK 0001595972 · VP Peripheral Nerve Science 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,432 F1 · shares: This reflects the number of shares that became vested as of February 15, 2022 upon the attainment of certain performance criteria. F2 · balance_after: Includes 2 shares acquired under the Axogen stock purchase plan on December 31, 2021. Read SEC document |
| December 27, 2021 Filed Dec 29, 2021 21:17 UTC | Axogen, Inc. AXGN · Entity 4297 | Exercise / conversionRestricted Stock Units · Derivative | 750 | $0.00 | $0.00 |
DisclosureSEC source: 0000805928-21-000179 · wf-form4_164081264670254.xml · derivative · entry 3 DeVinney Erick Wayne · CIK 0001595972 · VP Peripheral Nerve Science 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 750 Underlying: Common Stock · 1,500 shares Expires 2022-12-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock. F4 · derivative.exercise_date: All shares of AxoGen Inc. common stock underlying the restricted stock Units will be fully vested on December 27, 2022 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on December 27, 2020 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date. F4 · derivative.expiration_date: All shares of AxoGen Inc. common stock underlying the restricted stock Units will be fully vested on December 27, 2022 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on December 27, 2020 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date. Read SEC document |
| December 27, 2021 Filed Dec 29, 2021 21:17 UTC | Axogen, Inc. AXGN · Entity 4297 | Tax withholdingCommon Stock | 187 | $9.74 | $1,821.38 |
DisclosureSEC source: 0000805928-21-000179 · wf-form4_164081264670254.xml · nonDerivative · entry 2 DeVinney Erick Wayne · CIK 0001595972 · VP Peripheral Nerve Science 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,249 F2 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. Read SEC document |
| December 27, 2021 Filed Dec 29, 2021 21:17 UTC | Axogen, Inc. AXGN · Entity 4297 | Exercise / conversionCommon Stock | 750 | $0.00 | $0.00 |
DisclosureSEC source: 0000805928-21-000179 · wf-form4_164081264670254.xml · nonDerivative · entry 1 DeVinney Erick Wayne · CIK 0001595972 · VP Peripheral Nerve Science 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,436 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: This reflects the number of restricted stock units that vested on December 27, 2021. Read SEC document |
| December 20, 2021 Filed Dec 22, 2021 21:03 UTC | Axogen, Inc. AXGN · Entity 4297 | Exercise / conversionRestricted Stock Units · Derivative | 575 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000805928-21-000173 · wf-form4_164020697971757.xml · derivative · entry 3 DeVinney Erick Wayne · CIK 0001595972 · VP Peripheral Nerve Science 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 575 shares Expires 2021-12-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock. F4 · derivative.exercise_date: All shares of AxoGen Inc. common stock underlying the restricted stock Units will be fully vested on December 18, 2021 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on December 18, 2019 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date. Read SEC document |
| December 20, 2021 Filed Dec 22, 2021 21:03 UTC | Axogen, Inc. AXGN · Entity 4297 | Tax withholdingCommon Stock | 144 | $9.24 | $1,330.56 |
DisclosureSEC source: 0000805928-21-000173 · wf-form4_164020697971757.xml · nonDerivative · entry 2 DeVinney Erick Wayne · CIK 0001595972 · VP Peripheral Nerve Science 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 86,686 F2 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units on December 18, 2021. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. Read SEC document |
| December 20, 2021 Filed Dec 22, 2021 21:03 UTC | Axogen, Inc. AXGN · Entity 4297 | Exercise / conversionCommon Stock | 575 | $0.00 | $0.00 |
DisclosureSEC source: 0000805928-21-000173 · wf-form4_164020697971757.xml · nonDerivative · entry 1 DeVinney Erick Wayne · CIK 0001595972 · VP Peripheral Nerve Science 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 86,830 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: This reflects the number of restricted stock units that became vested as of December 18, 2021. Read SEC document |
| December 15, 2021 Filed Dec 17, 2021 21:02 UTC | Axogen, Inc. AXGN · Entity 4297 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $3.67 | $0.00 |
DisclosureSEC source: 0000805928-21-000172 · wf-form4_163977493108416.xml · derivative · entry 3 DeVinney Erick Wayne · CIK 0001595972 · VP Peripheral Nerve Science 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires 2021-12-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 15, 2021 Filed Dec 17, 2021 21:02 UTC | Axogen, Inc. AXGN · Entity 4297 | Tax withholdingCommon Stock | 4,171 | $8.80 | $36,704.80 |
DisclosureSEC source: 0000805928-21-000172 · wf-form4_163977493108416.xml · nonDerivative · entry 2 DeVinney Erick Wayne · CIK 0001595972 · VP Peripheral Nerve Science 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 86,255 F2 · shares: Represents the number of shares swapped to cover the exercise price of the options exercised via an attestation method stock swap in accordance with Rule16b-3. Read SEC document |
| December 15, 2021 Filed Dec 17, 2021 21:02 UTC | Axogen, Inc. AXGN · Entity 4297 | Exercise / conversionCommon Stock | 10,000 | $3.67 | $36,700.00 |
DisclosureSEC source: 0000805928-21-000172 · wf-form4_163977493108416.xml · nonDerivative · entry 1 DeVinney Erick Wayne · CIK 0001595972 · VP Peripheral Nerve Science 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,426 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: This reflects the number of shares that became vested as of December 29, 2018. Read SEC document |
| July 20, 2021 Filed Jul 21, 2021 20:16 UTC | Axogen, Inc. AXGN · Entity 4297 | Tax withholdingCommon Stock | 392 | $19.20 | $7,526.40 |
DisclosureSEC source: 0000805928-21-000148 · wf-form4_162689855941312.xml · nonDerivative · entry 2 DeVinney Erick Wayne · CIK 0001595972 · VP Peripheral Nerve Science 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,426 F2 · shares: The reported shares were sold, in compliance with company policy as to delivery of compensation based equity, with proceeds from such being used to cover the Reporting Person's tax withholding liability in connection with a portion of a performance stock award that vested on July 19, 2021. Read SEC document |
| July 19, 2021 Filed Jul 21, 2021 20:16 UTC | Axogen, Inc. AXGN · Entity 4297 | GrantCommon Stock | 1,580 | $0.00 | $0.00 |
DisclosureSEC source: 0000805928-21-000148 · wf-form4_162689855941312.xml · nonDerivative · entry 1 DeVinney Erick Wayne · CIK 0001595972 · VP Peripheral Nerve Science 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,818 F1 · shares: This reflects the number of shares that became vested as of July 19, 2021 upon the attainment of certain performance criteria. Read SEC document |
| April 28, 2021 Filed Apr 30, 2021 20:10 UTC | Axogen, Inc. AXGN · Entity 4297 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 10,000 | $2.86 Strike: $2.86 | $28,600.00 |
DisclosureSEC source: 0000805928-21-000076 · wf-form4_161981342959757.xml · derivative · entry 2 DeVinney Erick Wayne · CIK 0001595972 · VP of Clin. & Trans. Sciences 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires 2021-05-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: All shares pursuant to the employee stock option were fully vested on May 1, 2018 (4 years from the option grant date) based upon a vesting schedule whereby 25% of the aggregate shares vested on May 1, 2015 (12 months from the option grant date) and an additional 12.5% of the aggregate shares each 6 months thereafter. Read SEC document |
| April 28, 2021 Filed Apr 30, 2021 20:10 UTC | Axogen, Inc. AXGN · Entity 4297 | Exercise / conversionCommon Stock | 10,000 | $2.86 | $28,600.00 |
DisclosureSEC source: 0000805928-21-000076 · wf-form4_161981342959757.xml · nonDerivative · entry 1 DeVinney Erick Wayne · CIK 0001595972 · VP of Clin. & Trans. Sciences 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,082 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The Reporting Person has elected to exercise and hold the shares at this time. Read SEC document |
| March 16, 2021 Filed Mar 18, 2021 21:55 UTC | Axogen, Inc. AXGN · Entity 4297 | GrantRestricted Stock Units · Derivative | 11,800 | $0.00 | $0.00 |
DisclosureSEC source: 0000805928-21-000062 · wf-form4_161610449172937.xml · derivative · entry 2 DeVinney Erick Wayne · CIK 0001595972 · VP, Clinical&Translational Sc 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,800 Underlying: Common Stock · 11,800 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock. F3 · derivative.exercise_date: All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on March 16, 2025 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on March 16, 2023 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date. F3 · derivative.expiration_date: All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on March 16, 2025 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on March 16, 2023 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date. Read SEC document |
| March 16, 2021 Filed Mar 18, 2021 21:55 UTC | Axogen, Inc. AXGN · Entity 4297 | GrantEmployee Stock Option (right to purchase) · Derivative | 23,500 | $0.00 Strike: $20.91 | $0.00 |
DisclosureSEC source: 0000805928-21-000062 · wf-form4_161610449172937.xml · derivative · entry 1 DeVinney Erick Wayne · CIK 0001595972 · VP, Clinical&Translational Sc 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,500 Underlying: Common Stock · 23,500 shares Expires 2031-03-16 F1 · derivative.exercise_date: All shares of Axogen, Inc. common stock underlying the employee stock option will be fully vested on March 16, 2025 (4 years from the option grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on March 16, 2023 (24 months from the option grant date) and an additional 12.5% of the aggregate shares vest each 6 months thereafter. Read SEC document |
| February 17, 2021 Filed Feb 18, 2021 22:26 UTC | Axogen, Inc. AXGN · Entity 4297 | Tax withholdingCommon Stock | 322 | $18.70 | $6,021.40 |
DisclosureSEC source: 0000805928-21-000027 · wf-form4_161368715401383.xml · nonDerivative · entry 4 DeVinney Erick Wayne · CIK 0001595972 · VP, Clinical&Translational Sc 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,082 F2 · shares: The reported shares were sold, in compliance with company policy as to delivery of compensation based equity, with proceeds from such being used to cover the Reporting Person's tax withholding liability in connection with a portion of a performance stock award that vested on February 16, 2021. Read SEC document |
| February 17, 2021 Filed Feb 18, 2021 22:26 UTC | Axogen, Inc. AXGN · Entity 4297 | Tax withholdingCommon Stock | 1,542 | $18.70 | $28,835.40 |
DisclosureSEC source: 0000805928-21-000027 · wf-form4_161368715401383.xml · nonDerivative · entry 2 DeVinney Erick Wayne · CIK 0001595972 · VP, Clinical&Translational Sc 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,223 F2 · shares: The reported shares were sold, in compliance with company policy as to delivery of compensation based equity, with proceeds from such being used to cover the Reporting Person's tax withholding liability in connection with a portion of a performance stock award that vested on February 16, 2021. Read SEC document |
| February 16, 2021 Filed Feb 18, 2021 22:26 UTC | Axogen, Inc. AXGN · Entity 4297 | GrantCommon Stock | 1,181 | $0.00 | $0.00 |
DisclosureSEC source: 0000805928-21-000027 · wf-form4_161368715401383.xml · nonDerivative · entry 3 DeVinney Erick Wayne · CIK 0001595972 · VP, Clinical&Translational Sc 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,404 F1 · shares: This reflects the number of shares that became vested as of February 16, 2021 upon the attainment of certain performance criteria. Read SEC document |
| February 16, 2021 Filed Feb 18, 2021 22:26 UTC | Axogen, Inc. AXGN · Entity 4297 | GrantCommon Stock | 5,050 | $0.00 | $0.00 |
DisclosureSEC source: 0000805928-21-000027 · wf-form4_161368715401383.xml · nonDerivative · entry 1 DeVinney Erick Wayne · CIK 0001595972 · VP, Clinical&Translational Sc 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,765 F1 · shares: This reflects the number of shares that became vested as of February 16, 2021 upon the attainment of certain performance criteria. Read SEC document |
| December 29, 2020 Filed Dec 30, 2020 22:33 UTC | Axogen, Inc. AXGN · Entity 4297 | SaleCommon Stock | 371 | $17.81 | $6,607.51 |
DisclosureSEC source: 0001179110-20-012325 · edgar.xml · nonDerivative · entry 2 DeVinney Erick Wayne · CIK 0001595972 · VP, Clinical&Translational Sc 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,240 F2 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units granted on December 27, 2018. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. Read SEC document |
| December 27, 2020 Filed Dec 30, 2020 22:33 UTC | Axogen, Inc. AXGN · Entity 4297 | GrantCommon Stock | 1,500 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001179110-20-012325 · edgar.xml · nonDerivative · entry 1 DeVinney Erick Wayne · CIK 0001595972 · VP, Clinical&Translational Sc 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,611 F1 · shares: This reflects the number of restricted stock units that became vested as of December 27, 2020. F1 · price: This reflects the number of restricted stock units that became vested as of December 27, 2020. Read SEC document |
| December 21, 2020 Filed Dec 22, 2020 20:22 UTC | Axogen, Inc. AXGN · Entity 4297 | SaleCommon Stock | 147 | $16.42 | $2,413.74 |
DisclosureSEC source: 0001179110-20-012175 · edgar.xml · nonDerivative · entry 2 DeVinney Erick Wayne · CIK 0001595972 · VP, Clinical&Translational Sc 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,111 F2 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units granted on December 18, 2020. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. Read SEC document |
| December 18, 2020 Filed Dec 22, 2020 20:22 UTC | Axogen, Inc. AXGN · Entity 4297 | GrantCommon Stock | 575 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001179110-20-012175 · edgar.xml · nonDerivative · entry 1 DeVinney Erick Wayne · CIK 0001595972 · VP, Clinical&Translational Sc 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,258 F1 · shares: This reflects the number of restricted stock units that became vested as of December 18, 2020. F1 · price: This reflects the number of restricted stock units that became vested as of December 18, 2020. Read SEC document |
| December 15, 2020 Filed Dec 17, 2020 21:41 UTC | Axogen, Inc. AXGN · Entity 4297 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $4.81 | $0.00 |
DisclosureSEC source: 0001179110-20-012059 · edgar.xml · derivative · entry 3 DeVinney Erick Wayne · CIK 0001595972 · VP, Clinical&Translational Sc 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,000 shares Expires 2021-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 15, 2020 Filed Dec 17, 2020 21:41 UTC | Axogen, Inc. AXGN · Entity 4297 | Tax withholdingCommon Stock | 4,373 | $16.50 | $72,154.50 |
DisclosureSEC source: 0001179110-20-012059 · edgar.xml · nonDerivative · entry 2 DeVinney Erick Wayne · CIK 0001595972 · VP, Clinical&Translational Sc 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,683 F2 · shares: Represents the number of shares swapped to cover the exercise price of the options exercised via an attestation method stock swap in accordance with Rule 16b-3. Read SEC document |
| December 15, 2020 Filed Dec 17, 2020 21:41 UTC | Axogen, Inc. AXGN · Entity 4297 | Exercise / conversionCommon Stock | 15,000 | $4.81 | $72,150.00 |
DisclosureSEC source: 0001179110-20-012059 · edgar.xml · nonDerivative · entry 1 DeVinney Erick Wayne · CIK 0001595972 · VP, Clinical&Translational Sc 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,056 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: This reflects the number of shares that became vested as of January 2, 2018. Read SEC document |
| April 28, 2020 Filed Apr 29, 2020 21:56 UTC | Axogen, Inc. AXGN · Entity 4297 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 2,530 | $0.00 Strike: $0.27 | $0.00 |
DisclosureSEC source: 0001179110-20-005269 · edgar.xml · derivative · entry 2 DeVinney Erick Wayne · CIK 0001595972 · VP, Clinical&Translational Sc 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,530 shares Expires 2020-06-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 28, 2020 Filed Apr 29, 2020 21:56 UTC | Axogen, Inc. AXGN · Entity 4297 | Exercise / conversionCommon Stock | 2,530 | $0.27 | $683.10 |
DisclosureSEC source: 0001179110-20-005269 · edgar.xml · nonDerivative · entry 1 DeVinney Erick Wayne · CIK 0001595972 · VP, Clinical&Translational Sc 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,056 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: This Form is being filed to report the cash exercise of a stock option for a total of 2,530 shares. Read SEC document |
| March 16, 2020 Filed Mar 18, 2020 21:15 UTC | Axogen, Inc. AXGN · Entity 4297 | GrantRestricted Stock Units · Derivative | 12,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-20-003913 · edgar.xml · derivative · entry 2 DeVinney Erick Wayne · CIK 0001595972 · VP, Clinical&Translational Sc 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,000 Underlying: Common Stock · 12,000 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock. F3 · derivative.exercise_date: All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on March 16, 2024 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on March 16, 2022 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date. F3 · derivative.expiration_date: All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on March 16, 2024 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on March 16, 2022 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date. Read SEC document |
| March 16, 2020 Filed Mar 18, 2020 21:15 UTC | Axogen, Inc. AXGN · Entity 4297 | GrantEmployee Stock Option (right to purchase) · Derivative | 24,000 | $0.00 Strike: $8.61 | $0.00 |
DisclosureSEC source: 0001179110-20-003913 · edgar.xml · derivative · entry 1 DeVinney Erick Wayne · CIK 0001595972 · VP, Clinical&Translational Sc 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,000 Underlying: Common Stock · 24,000 shares Expires 2030-03-16 F1 · derivative.exercise_date: All shares of Axogen, Inc. common stock underlying the employee stock option will be fully vested on March 16, 2024 (4 years from the option grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on March 16, 2022 (24 months from the option grant date) and an additional 12.5% of the aggregate shares vest each 6 months thereafter. Read SEC document |
| February 18, 2020 Filed Feb 20, 2020 18:19 UTC | Axogen, Inc. AXGN · Entity 4297 | Tax withholdingCommon Stock | 351 | $14.68 | $5,152.68 |
DisclosureSEC source: 0001179110-20-001943 · edgar.xml · nonDerivative · entry 4 DeVinney Erick Wayne · CIK 0001595972 · VP, Clinical&Translational Sc 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,526 F2 · shares: The reported shares were withheld to cover the Reporting Person's tax withholding liability in connection with a portion of a performance stock award that vested on February 18, 2020. Read SEC document |
| February 18, 2020 Filed Feb 20, 2020 18:19 UTC | Axogen, Inc. AXGN · Entity 4297 | GrantCommon Stock | 1,181 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-20-001943 · edgar.xml · nonDerivative · entry 3 DeVinney Erick Wayne · CIK 0001595972 · VP, Clinical&Translational Sc 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,877 F1 · shares: This reflects the number of shares that became vested as of February 18, 2020 upon the attainment of certain performance criteria. F1 · price: This reflects the number of shares that became vested as of February 18, 2020 upon the attainment of certain performance criteria. Read SEC document |
| February 18, 2020 Filed Feb 20, 2020 18:19 UTC | Axogen, Inc. AXGN · Entity 4297 | Tax withholdingCommon Stock | 1,498 | $14.68 | $21,990.64 |
DisclosureSEC source: 0001179110-20-001943 · edgar.xml · nonDerivative · entry 2 DeVinney Erick Wayne · CIK 0001595972 · VP, Clinical&Translational Sc 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,696 Read SEC document |
| February 18, 2020 Filed Feb 20, 2020 18:19 UTC | Axogen, Inc. AXGN · Entity 4297 | GrantCommon Stock | 5,049 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-20-001943 · edgar.xml · nonDerivative · entry 1 DeVinney Erick Wayne · CIK 0001595972 · VP, Clinical&Translational Sc 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,194 F1 · shares: This reflects the number of shares that became vested as of February 18, 2020 upon the attainment of certain performance criteria. F1 · price: This reflects the number of shares that became vested as of February 18, 2020 upon the attainment of certain performance criteria. Read SEC document |
| December 18, 2019 Filed Dec 20, 2019 21:27 UTC | Axogen, Inc. AXGN · Entity 4297 | Tax withholdingCommon Stock | 281 | $16.73 | $4,701.13 |
DisclosureSEC source: 0001179110-19-013085 · edgar.xml · nonDerivative · entry 2 DeVinney Erick Wayne · CIK 0001595972 · VP, Clinical&Translational Sc 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,840 F2 · shares: The reported shares were withheld to cover the Reporting Person's tax withholding liability in connection with a portion of the restricted stock units that vested on December 18, 2019. Read SEC document |
| December 18, 2019 Filed Dec 20, 2019 21:27 UTC | Axogen, Inc. AXGN · Entity 4297 | GrantCommon Stock | 1,150 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001179110-19-013085 · edgar.xml · nonDerivative · entry 1 DeVinney Erick Wayne · CIK 0001595972 · VP, Clinical&Translational Sc 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,121 F1 · shares: This reflects the number of restricted stock units that became vested as of December 18, 2019. F1 · price: This reflects the number of restricted stock units that became vested as of December 18, 2019. Read SEC document |
| February 15, 2019 Filed Feb 19, 2019 18:24 UTC | Axogen, Inc. AXGN · Entity 4297 | Tax withholdingCommon Stock | 1,498 | $17.57 | $26,319.86 |
DisclosureSEC source: 0001179110-19-002053 · edgar.xml · nonDerivative · entry 2 DeVinney Erick Wayne · CIK 0001595972 · VP, Clinical&Translational Sc 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,971 F2 · shares: The reported shares were withheld to cover the Reporting Person's tax withholding liability in connection with a portion of a performance stock award that vested on February 15, 2019. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.